

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
-------------------------	----------------

NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
------------------------------	--------------------------

CONVEYING PARTY DATA	
Name	Execution Date
Whitebox Advisors, LLC, as Collateral Agent	03/13/2007

RECEIVING PARTY DATA	
Name:	Humanetics Corporation
Street Address:	10400 Viking Drive, Suite 100
City:	Eden Prairie
State/Country:	MINNESOTA
Postal Code:	55344

PROPERTY NUMBERS Total: 26

Property Type	Number
Patent Number:	6924274
Patent Number:	6794374
Patent Number:	6489313
Patent Number:	6399085
Patent Number:	6399084
Patent Number:	6384251
Patent Number:	6372732
Patent Number:	6153606
Patent Number:	6111118
Patent Number:	5885977
Patent Number:	5869709
Patent Number:	5807848
Patent Number:	5707983
Patent Number:	5641766
Patent Number:	5585371

CH \$1040.00 6924274

Patent Number:	5506223
Patent Number:	5424463
Patent Number:	5296481
Patent Number:	5292730
Patent Number:	4897390
Patent Number:	6252119
Patent Number:	6465446
Patent Number:	6518318
Patent Number:	6593316
Patent Number:	6686486
Application Number:	10340980

CORRESPONDENCE DATA

Fax Number: (312)577-4565
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 312-577-8265
Email: kristin.brozovic@kattenlaw.com
Correspondent Name: Kristin Brozovic c/o Katten Muchin
Address Line 1: 525 W Monroe
Address Line 4: Chicago, ILLINOIS 60661

ATTORNEY DOCKET NUMBER:	334895-13
NAME OF SUBMITTER:	Kristin Brozovic

Total Attachments: 5
source=Patent Release#page1.tif
source=Patent Release#page2.tif
source=Patent Release#page3.tif
source=Patent Release#page4.tif
source=Patent Release#page5.tif

PATENT RELEASE AND REASSIGNMENT

THIS PATENT RELEASE AND REASSIGNMENT is made as of March 13, 2007, by Whitebox Advisors, LLC, as Collateral Agent ("Agent").

WITNESSETH:

WHEREAS, Agent and Humanetics Corporation, a Minnesota corporation ("Borrower"), were parties to that certain Patent and Trademark Security Agreement dated as of April 21, 2005 (the "Security Agreement"; capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Security Agreement), pursuant to which Borrower granted a security interest to Agent in, among other things, the Patents (as defined in the Security Agreement) as security for certain obligations owing by Borrower to the financial institutions (collectively, the "Lenders"), including the Patents set forth on Exhibit A hereto; and

WHEREAS, the Security Agreement was recorded by the Assignment Division of the United States Patent and Trademark Office on February 14, 2006, at Reel 017164, Frame 0276; and

WHEREAS, Borrower has requested that Agent release its security interest in the Patents and reassign the same to Borrower;

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged:

1. Agent hereby releases its security interest in all of Borrower's right, title and interest in and to all of the following:

(a) all patents, registered patents, patent applications, including, without limitation, the registered patents and patent applications listed on Exhibit A attached hereto and made a part hereof, and (i) all renewals thereof, (ii) all income, royalties, damages and payments now and hereafter due and/or payable under and with respect thereto, including, without limitation, payments under all licenses entered into in connection therewith and damages and payments for past or future infringements or dilutions thereof, (iii) the right to sue for past, present and future infringements and dilutions thereof, and (iv) all of Borrower's rights corresponding thereto throughout the world (all of the foregoing registered patents and patent applications, together with the items described in clauses (i)-(iv) in this paragraph (a), are sometimes hereinafter individually and/or collectively referred to as the "Released Patents");

(b) all rights under or interests in any patent license agreements with any other party, whether Borrower is a licensee or licensor under any such license agreement, including, without limitation, those patent license agreements listed on

Exhibit A attached hereto and made a part hereof, and the right to prepare for sale and sell any and all Inventory now or hereafter owned by Borrower and now or hereafter covered by such licenses; and

(c) all proceeds of the foregoing.

2. Agent hereby reassigns, grants and conveys to Borrower, without any representation, warranty, recourse or undertaking by Agent, all of Agent's right, title and interest in and to the Released Patents.

*- Remainder of Page Intentionally Left Blank –
[Signature Page Follows]*

IN WITNESS WHEREOF, Agent has caused this Patent Release and Reassignment to be duly executed by its duly authorized officer as of the day and year first above written.

WHITEBOX ADVISORS, LLC, as
Collateral Agent on behalf of Whitebox
Hedged High Yield Partners, L.P. and Curtis
A. Sampson

By: 

Name: Jonathan Wood

Title: Chief Financial Officer/Director

EXHIBIT A to Patent Release and Reassignment

<u>Patent</u>	<u>Patent Number</u>	<u>Filing Date</u>	<u>Application Number</u>	<u>Application Date</u>
Method of modulating the basalmetabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal	N/A	N/A	10-340980	1/13/2003
Use of DELTA 5- Androstene-3 beta-OL7,17-dione in the Treatment of Lupus Erythematosus	6924274	8/2/2005	10-431960	5/8/2003
Use of DELTA 5- Androstene-3 beta-OL7,17-dione in the Treatment of Arthritis	6794374	9/21/2004	09-554951	11/27/2000
Memory by the Administration of DELTA 5-androstene-3 beta--ol-7, 17-dione and 3 beta esters	6489313	12/3/2002	09-704495	11/1/2000
Method for Moisturizing the Skin by the Topical Application of DELTA 5-androstene-3 beta-ol-7, 17 dione and Metabolizeable Precursors thereof	6399085	6/4/2002	09-799313	3/5/2001
Method for Diminishing Wrinkles and Fine Lines of the Skin by the Topical Application of DELTA 5-androstene- 3 beta- ol-7, 17 dione and Metabolizable Precursors thereof	6399084	6/4/2002	09-799295	3/5/2001
Process for Effecting Allylic Oxidation Using Dicarboxylic Acid Imides and Chromium Reagents	6384251	5/7/2002	09-423467	11/8/1999
Use of DELTA 5- androstene-3 beta- ol- 7, 17- dione in the Treatment of Lupus Erythematosus	6372732	4/16/2002	09-554952	12/4/2000
Memory Enhancement by the Administration of DELTA 5- androstene- 3 beta- ol-7, 17- dione and 3 beta esters thereof	6153606	11/28/2000	09-174235	10/16/1998
Process for Effecting Allylic Oxidation	6111118	8/29/2000	09-228902	1/11/1999
Use of DELTA 5 androstenes in the Treatment of HIV Wasting Syndrome	5885977	3/23/1999	09-784856	1/15/1997

<u>Patent</u>	<u>Patent Number</u>	<u>Filing Date</u>	<u>Application Number</u>	<u>Application Date</u>
Process for Effecting Allylic Oxidation	5869709	2/9/1999	08-851939	5/7/1997
Use of Dehydroepiandrosterone-3-Carboxylates to Control Body Weight	5807848	9/15/1998	08-771335	12/16/1996
Treatment of Alzheimer's Disease and Modulation of Immune System with DELTA 5- androstenes	5707983	1/13/1998	08-806541	2/24/1997
UP- Regulation of Immune System with DELTA 5- Androstenes	5641766	6/24/1997	08-527746	9/13/1995
Treatment of Immune System with DELTA 5- Androstenes	5585371	12/17/1996	08-189917	2/2/1994
DELTA 5- Androstenes Useful for Promoting Weight Maintenance or Weight Loss and Treatment Process	5506223	4/9/1996	08-327646	10/24/1994
DELTA 5- Androstenes Useful for Promoting Weight Maintenance or Weight Loss and Treatment Process	5424463	6/13/1995	08-327843	10/24/1994
Treatment Process for Promoting Weight Loss Employing a Substituted DELTA 5	5296481	3/22/1994	07-867288	4/10/1992
Modulation of Immune System with DELTA 5- Androstenes	5292730	3/8/1994	07-922850	7/31/1992
Novel Anti-Obesity Compounds and Method of Use	4897390	1/30/1990	07-076077	7/21/1987
Copper-Catalysed Allylic Oxidation Using Alkyl Hydroperoxide	6252119	6/26/2001	08-901764	7/28/1997
Treatment of Dermatitis by the Topical Application of 5- Androstene- 3 beta-ol-7, 17 dione and Metabolizable Precursors thereof	6465446	10/15/2002	09-805024	3/12/2001
Stimulating Transport of Glucose into Animal Tissue by the Administration of Pinitol	6518318	2/11/2003	09-857245	5/30/2001
Use of DELTA 5-Androstene-3beta-ol-7, 17- dione in the Treatment of Lupus Erythematosus	6593316	7/15/2003	10-106580	3/22/2002
Process of Effecting Allylic Oxidation	6686486	2/3/2004	09-639027	8/14/2000